Health Innovation for All
By Mariana Mazzucato, Jayati Ghosh  |  Feb 02, 2022
Health Innovation for All
Image courtesy of and under license from
The new Omicron variant is a reminder that the system for managing global health emergencies remains woefully inadequate.

LONDON - Despite multiple technological breakthroughs in the fight to control COVID-19, twice as many people died from it in 2021 compared to 2020. The Omicron variant is a stark reminder that effective vaccines are merely the first step toward ending the pandemic. Until we establish a process to manufacture vaccines at scale and distribute them where they are needed, we will lack the collective capacity to curb this or any future pandemic.

The shameful inequity in global vaccine distribution shows that we cannot rely on monopolies, commercial imperatives, and charitable efforts alone if we are to achieve the World Health Organization’s (WHO) goal of ‘Health for All.’ As the WHO’s Independent Panel on Pandemic Preparedness and Response concludes, we need a globally coordinated, end-to-end innovation system in which intellectual property (IP) rules and fiscal policies are designed to support collaboration between the public and private sectors. The quantity and quality of financing must be restructured around the overriding goal of delivering essential health technologies as a global common good.

The content herein is subject to copyright by Project Syndicate. All rights reserved. The content of the services is owned or licensed to The Yuan. The copying or storing of any content for anything other than personal use is expressly prohibited without prior written permission from The Yuan, or the copyright holder identified in the copyright notice contained in the content.
Continue reading
Buy this article for only US$1.99
- or -
Continue with Linkedin Continue with Google
Share your thoughts.
The Yuan wants to hear your voice. We welcome your on-topic commentary, critique, and expertise. All comments are moderated for civility.